Twenty-seven states and the District of Columbia have filed a lawsuit against 23andMe regarding the sale of customer DNA data without direct consent. The lawsuit, filed in U.S. Bankruptcy Court, argues that consent from each customer is necessary before their sensitive genetic information can be sold. 23andMe, a genetic-testing company known for its ancestry and health reports, is facing bankruptcy and is set for acquisition by Regeneron Pharmaceuticals. The lawsuit underscores significant concerns over privacy and the handling of personal DNA data, which is regarded as both permanent and private.
The suit argues that 23andMe needs permission from every customer before selling their data, highlighting the importance of consent in handling sensitive DNA information.
This isn't just data—it's your DNA. It's personal, permanent and deeply private, emphasizing that consumers had no intention for their genetic info to be sold.
The lawsuit raises concerns over consumer privacy amid 23andMe's financial issues, as the company prepares for a $256 million acquisition by Regeneron Pharmaceuticals.
Collection
[
|
...
]